2,518 views
With nearly one in five cancer patients affected by thromboembolic disease, Corinne Frère, hematologist-biologist, speaking to Franck Thuny, summarizes the therapeutic specificities and the conduct to be adopted by cardiologists according to the recommendations of the ASCO (American Society of Clinical Oncology) or those of the ESC (European Society of Cardiology) and the ITAC (the International Initiative on Thrombosis and Cancer). What are the cancers with a high risk of bleeding? What are the specificities for treatments: LMWH, DOAC, AVK? What should be done in the face of thrombocytopenia in these patients?